Quality Comparison of Biosimilar and Copy Filgrastim Products With the Innovator Product

Pharmaceutical Research - United States
doi 10.1007/s11095-018-2491-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Comparison of the Pharmacodynamic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial

Annals of Hematology
MedicineHematology
2010English

Pharmacokinetic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial

Annals of Hematology
MedicineHematology
2010English

Regulatory and Clinical Experiences With Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada

Oncologist
Cancer ResearchMedicineOncology
2019English

Filgrastim-SNDZ Debuts as the First Biosimilar Approved in United States

Journal of Community and Supportive Oncology
OncologyHematology
2015English

Expanded Access to Cancer Treatments From Conversion to Neutropenia Prophylaxis With Biosimilar Filgrastim-SNDZ

Future Oncology
MedicineCancer ResearchOncology
2017English

Pcn32 - The Effectiveness and Safety of Switching From Orginal Filgrastim to Biosimilar Filgrastim in Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia: A Retrospective Cohort Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comparative Studies of Biosimilar Medicinal Products

The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products
2019English

Cross-National Comparison of Biosimilar Medicines : Market Penetration and Competition With Originators

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy